Dosage forms having prolonged active ingredient release

Details Dosage forms having prolonged active ingredient release Dosage forms having prolonged active ingredient release

A - Human Necessities

61

K

A61K 31/44 (2006.01) A61K 9/20 (2006.01) A61K 9/28 (2006.01)

Patent

CA 2086989

Abstract Pharmaceutical dosage forms having a linear release rate of the 0th order for the once-daily oral administration of 20 - 120 mg of nifedipine or of another calcium antagonist of the dihydropyridine type, characterised by a homogeneous matrix containing 2 - 50 % by weight of hydroxypropyl- methylcellulose having an average molecular weight of 20,000 - 250,000, 5 - 60 % by weight of a calcium anta- gonist of the dihydropyridine type, as well as customary excipients compatible with the formulation, such as lipophilic or hydrophilic liberation controllers, fillers, flow-regulating agents, lubricants and, optionally, film coatings.

Affiliated with

Also associated with

Rating

Dosage forms having prolonged active ingredient release does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dosage forms having prolonged active ingredient release, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dosage forms having prolonged active ingredient release will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1895099